Daiichi Sankyo Escapes Antitrust MDL Over Generic Lipitor

Law360, Washington (November 19, 2013, 12:52 PM EST) -- A New Jersey federal judge on Monday released Daiichi Sankyo Inc. from multidistrict antitrust litigation challenging a patent infringement settlement between Pfizer Inc. and Ranbaxy Laboratories Inc. over Pfizer's cholesterol drug Lipitor, in which Daiichi Sankyo claimed it had no involvement.

In a short order, U.S. District Judge Peter G. Sheridan dismissed the case against Daiichi from the case, where several California pharmacies claimed it was involved in Ranbaxy Pharmaceuticals Inc.'s alleged anti-competitive agreement with Pfizer to delay generic Lipitor competition for longer than necessary....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.